Human Growth Hormone Market To Hit Value .5 Billion By 2027

Posted by Mrudula Anil Karmarkar on April 5th, 2022

The global human growth hormone market size is expected to reach a value of USD 8.5 billion by 2027, registering a CAGR of 8.2% over the forecast period, according to a new report by Grand View Research, Inc. Introduction of novel therapies, increasing R&D activities, and the rising awareness for the diagnosis and treatment of growth hormone (GH) disorders are expected to drive the market over the forecast period.

Key players operating in the market are involved in extensive R&D activities for the development of novel GH therapies to strengthen their position in the market. For instance, in October 2020, VISEN Pharmaceuticals, a joint venture of Denmark-based Ascendis Pharma A/S, received approval from the China National Drug Administration (NMPA) for its new drug (IND) application to start Phase III clinical study of TransCon hGH. Furthermore, two South Korean companies, Genexine Inc. and Handok Inc. are conducting a Phase II clinical trial study on GX-H9, a recombinant human GH for the treatment of adult and pediatric GH deficiency.

Furthermore, an increase in the number of regulatory approvals and the launch of novel HGH therapies are expected to fuel the market over the forecast period. For instance, in January 2018, Ferring Pharmaceuticals Inc., a Switzerland-based pharmaceutical company, received United States Food and Drug Administration (USFDA) approval for its new recombinant HGH, Zomacton (somatropin), indicated for the treatment of adult patients with GH deficiency.

Various government and private organizations have been undertaking initiatives and programs to spread awareness about GH deficiency and facilitate timely diagnosis and treatment. Nonprofit organizations such as the Human Growth Foundation are engaged in providing research support and spreading awareness about GH deficiency and its treatment. Such initiatives are expected to drive the demand for hGH treatment therapies.

Human growth hormone (HGH), also known as somatotropin, is a peptide hormone responsible for growth stimulation, cell reproduction, and cell regeneration in humans and is hence important for human development. Growth hormone (GH) deficiency in humans is caused when the pituitary gland does not synthesize enough concentration of hGH. This deficiency in humans is treated by administering recombinant human growth hormone by subcutaneous injection. Various genetic disorders, including Prader-Willi syndrome and Turner syndrome, may also cause growth hormone deficiency in humans, leading to delayed puberty and shorter-than-average height.

To Request Sample Copy of this report, click the link:

https://www.grandviewresearch.com/industry-analysis/human-growth-hormone-drugs-market/request/rs1

According to data published by the American Academy of Pediatrics, growth hormone deficiency among humans is a rare condition and affects less than one in 3,000 to one in 10,000 children in U.S. Currently, hGH is widely abused as an anti-aging treatment in older adults and as a performance-enhancing anabolic drug by bodybuilders and athletes. However, HGH is a controlled substance as per the USFDA and has not been approved for anti-aging and performance-enhancing indications.

Human Growth Hormone Market Report Highlights

  • GH deficiency was the largest application segment in 2020 owing to an increase in regulatory approvals and the launch of novel therapies
  • Rising awareness about GH deficiency, coupled with increasing hospital visits for its treatment, is expected to drive the hospital pharmacy distribution channel segment
  • North America dominated the human growth hormone market with the largest share in 2020. This is attributed to favorable reimbursement scenario, high awareness, and the presence of major players in the region
  • Asia Pacific is projected to witness a lucrative CAGR over the forecast period owing to increasing penetration of key players with their new growth hormone therapies
  • The key players include Novo Nordisk A/S; Pfizer Inc.; Eli Lilly and Company; Sandoz International GmbH (Novartis AG); Merck KGaA; Genentech, Inc. (Roche); Ferring Pharmaceuticals; Teva Pharmaceutical Industries, Ltd; and Ipsen.

Some of the key players operating in the market are Novo Nordisk A/S; Pfizer, Inc.; Eli Lilly and Company; Sandoz International GmbH (Novartis AG); Merck KGaA; Genentech, Inc. (Roche); Ferring Pharmaceuticals; Teva Pharmaceutical Industries, Ltd; and Ipsen. Several companies focus on developing long-acting human growth hormones.

The major companies operating in the market are adopting mergers, partnerships, and acquisitions as key strategies to expand their geographic reach and provide access to their solutions. For instance, in October 2018, Novo Nordisk and Strongbridge Biopharma signed an agreement to acquire the rights to MACRILEN in the U.S. and Canada. MACRILEN (macimorelin) is the first and only oral drug approved by the FDA for use in adult growth hormone deficiency diagnosis.

Like it? Share it!


Mrudula Anil Karmarkar

About the Author

Mrudula Anil Karmarkar
Joined: July 2nd, 2020
Articles Posted: 1,808

More by this author